Kornimate/medical-research-clean huggingface dataset:
effect of (neo)adjuvant therapy on lipids in young breast cancer patients

Conditions: Breast Neoplasms; Lipid Profile

Summary: previous studies have shown differences in the effects of different endocrine drugs on blood lipids in breast cancer, and dyslipidaemia is a major risk factor for cardiovascular disease, and it has been previously reported that the leading cause of death in postmenopausal patients with breast cancer is cardiovascular disease, but the effects of endocrine drug therapy on blood lipids in young breast cancer patients (age ≤40) are not clear. previously, our group conducted a preliminary retrospective analysis of young patients on endocrine therapy and found that dyslipidaemia was also a common adverse effect of treatment in young breast cancer patients; therefore, dyslipidaemia induced by antineoplastic therapy not only occurs in postmenopausal patients, but is also prevalent in premenopausal and even younger patients. therefore, this study intends to evaluate the effects of different treatment regimens on lipids in early-stage young breast cancer patients and to explore the optimal timing of lipid-lowering drug interventions to provide a basis for clinical practice.


Eligibility criteria:
inclusion criteria: * ecog score 0-1 * resectable breast cancer * no distant metastases on postoperative imaging assessment * patients proposed for (neo)adjuvant therapy * no previous oral lipid-lowering drugs, serum ldl-c level within normal range, i.e. ldl-c value: \&lt;3.4 mmol/l * no fatty liver by liver ultrasound/ct examination * no major organ dysfunction exclusion criteria: * patients with pre-existing hyperlipidaemia, coronary heart disease, fatty liver disease, or who have received or are receiving lipid-lowering medication * enrolled in another study or less than or equal to 4 weeks since discontinuation of other medications * presence of severe dysfunction of vital organs * patients with other malignancies (except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumours that have been cured for at least 5 years) * acute infectious diseases or chronic infectious diseases in active stage * history of uncontrolled epilepsy, central nervous system disease or mental disorder
comparison of the efficacy of clindamycin phosphate 1% gel versus once-daily dapsone 5% gel in the treatment of moderate acne vulgaris

Conditions: Acne Vulgaris

Summary: acne vulgaris (av) is a disease of the pilosebaceous unit that causes noninflammatory lesions (open and closed comedones), inflammatory lesions (papules, pustules, and nodules), and varying degrees of scarring. the key pathogenic processes includes alteration of follicular keratinization that leads to comedones; increased and altered sebum production under androgen control; follicular colonization by propionibacterium acnes; . the role of topical antibiotics in treating acne is well established. clindamycin is a topical antibiotic which has been widely used in treatment of acne for many decades. the extensive use of antibiotics in acne has lead to the development of resistance to antimicrobial therapy. dapsone is known to have antibacterial as well as anti-inflammatory action which may help in reduction of acne.

topical dapsone 5% gel contains sulfone and has an advanced solvent micro particulate delivery system that enables penetration of stratum corneum . it is a new topical drug used in the treatment of moderate acne vulgaris.

Eligibility criteria:
inclusion criteria: * moderate acne vulgaris * either gender * 20 to 50 yrs exclusion criteria: * systemic treatment taken * pregnant or lactating women * hematological abnormalities
observational study to investigate the long-term effects of mircera in clinical routine

Conditions: Anemia

Summary: this observational study will assess the effect of long-term treatment with mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients with renal anemia. data will be collected from each patient for at least 24 months.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * patients with chronic kidney disease (ckd), stages iv and v * treatment with mircera according to label exclusion criteria: * pregnant or breastfeeding women
cytomegalovirus infection in patients with hiv-1 infection

Conditions: Cytomegalovirus Infections; HIV-1-infection

Summary: the purpose of this study is to assess the level of cd4 and cd8 t cell activation in an observational cohort study of hiv-1 patients, virosuppressed on combined antiretroviral therapy (\< 50 copies/ml) for at least 2 years and to focus on two factors that could participate in this activation: cytomegalovirus infection and auto-immune disorders.

t cell activation plays a central role in hiv pathogenesis and is highly correlated to disease progression even in hiv patients virosuppressed on combined antiretroviral therapy since years. the mechanisms underlying this activation in virosuppressed patients are poorly understood. identifying some factors involved in immune activation that can be targeted by therapies could optimize the treatment of hiv patients. the purpose of this study is to assess the level of cd4 and cd8 t cell activation in an observational cohort study of hiv-1 patients, virosuppressed on combined antiretroviral therapy (\< 50 copies/ml) for at least 2 years and to focus on two factors that could participate in this activation: cytomégalovirus infection and auto-immune disorders.

Eligibility criteria:
inclusion criteria: * patients included in the aquitaine anrs co3 cohort aged 18 years or older (confirmed hiv-1 infection and at least one follow-up in the cohort), * plasma hiv-1 rna \<50 copies / ml for at least 24 months under a highly active antiretroviral combination (treatment comprising at least 3 antiretroviral drugs) modified or initiated between 2005 and 2008, * follow-up in one of the departments of bordeaux university hospital or libourne hospital, * free, informed and written consent, signed by the patient and the investigator (consent of the aquitaine co3 cohort and linked to this specific study). exclusion criteria: * presence of 2 consecutive measurements of hiv rna\> 50 copies / ml, * history of immunotherapy treatments (interleukin-2), * hepatitis b or c co-infections, * pregnancy * breastfeeding * symptomatic infectious episode in progress.
response of clostridium difficile infection to metronidazole therapy

Conditions: Clostridium Enterocolitis; Pseudomembranous Colitis; Antibiotic-Associated Colitis

Summary: in this record review study, our objective is to determine the rates of cure, failure and relapse following treatment of c. difficile colitis with metronidazole.

clostridium difficile is a major cause of nosocomial infection. when this organism proliferates in the colon, usually as a result of prior antibiotic therapy in a hospitalized or otherwise debilitated person, a variety of potentially serious consequences follow, such as fever, leukocytosis, abdominal pain, diarrhea and ileus. some patients require surgical exploration and colectomy, and our hospital has had several deaths attributable to c. difficile colitis in the past year. c. difficile colitis is treated with metronidazole, and earlier literature on this subject, written in the 1980's and early 1990s, suggests that the response rate is excellent, exceeding 90-95%. our clinical observation has suggested that treatment with metronidazole is followed by a surprisingly high rate of failure, perhaps 25-30%. the clinical problem is that there are, at present, no desirable alternatives. vancomycin, given orally, is said to be highly effective in treating this infection, but this may not be true, and the administration of this drug is associated with emergence of vancomycin-resistant bacteria, a major problem in modern hospitals. no other drug is approved for treatment of c. difficile infection. we believe it is important to determine the actual rate of failure of treatment with metronidazole. this will provide an impetus for developing new therapeutic approaches. we will review the records of patients who have been treated for confirmed c. difficile infection with metronidazole at the vamc for the past 12 months in order to determine the rates of cure, failure, and relapse following therapy. this is a simple record review study to determine if our clinical suspicion is correct, namely, if the rate of failure of metronidazole therapy is much higher than that reported in the medical literature of 10-15 years ago.

Eligibility criteria:
inclusion criteria: * records of patients who have a fecal sample positive for c. difficile toxin and who are then treated for c. difficile colitis with oral metronidazole will be included in this study. exclusion criteria: * patients who did not receive at least 7 days of metronidazole

Keywords: clostridium difficile
study comparing risperidone vs placebo as add-on therapy in patients with generalized anxiety disorder who are sub-optimally responding to standard therapy.

Conditions: Anxiety Disorders

Summary: the purpose of this trial is to determine the effectiveness of risperidone as an adjunctive treatment in patients with gad who demonstrate a less-than-optimal response to their current anxiolytic treatment.

many patients with generalized anxiety disorder (gad) do not benefit or show only partial benefit from current psychotropic therapies. this trial was conducted for the purpose of determining the effectiveness of risperidone as an adjunctive treatment in patients with gad who demonstrate a less-than-optimal response to their current anxiolytic treatment (either allowed antidepressants, benzodiazepines, or buspirone, or combination). patients were randomized (patients are assigned different treatments based on chance) to either risperidone or placebo for 4 - 6 weeks of double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage) treatment. patients randomized to risperidone continued on their current anxiolytic treatment (treatment for anxiety) and received risperidone 0.25 mg per day for the first 3 days, 0.5 mg per day for days 4 through 14, and 1 mg per day for days 15 through 28 of the trial. if clinically indicated, on day 29, the dose could be increased to 2 mg per day for the rest of the trial (4 to 6 additional weeks). at each dose level, risperidone was taken by mouth in a single daily dose. patients were asked questions every one or two weeks, depending on the phase of the trial, to determine efficacy (effectiveness) and safety. the study hypothesis is that risperidone will be more effective as an adjunct to standard psychotropic treatments for symptoms of generalized anxiety disorder than placebo, as measured by a composite of the four most troubling symptoms identified at baseline. risperidone 0.25 mg per day for the first 3 days, 0.5 mg per day for days 4 through 14, and 1 mg per day for days 15 through 28 of the trial. if clinically indicated, on day 29, the dose could be increased to 2 mg per day for the rest of the trial (4 to 6 additional weeks). at each dose level, risperidone was taken by mouth in a single daily dose.

Eligibility criteria:
inclusion criteria: * healthy on the basis of physical exam * treatment with one or more allowed antidepressants and/or anxiety medications for at least the past 8 weeks * judgement of the clinician that the patient has shown a sub-optimal response to this treatment * current diagnosis of generalized anxiety disorder * maintained on a stable, therapeutic dose(s) of the allowed medication(s) for at least the past four weeks exclusion criteria: * presence of other serious medical illnesses * active use of cocaine or heroin * history of suicide attempt in past 12 months * changes to antidepressant/anti-anxiety regimen (medication or dose) within the four weeks preceding study baseline (day 1) * history of clozapine use

Keywords: anxiety antipsychotic
octa study: retinal vascular changes in patients with sars-cov-2 infection

Conditions: Covid19

Summary: this study evaluates the retinal vascular features using optical coherence tomography angiography in patients that have been affected by covid-19.

to investigate the potential role of optical coherence tomography angiography in identifying the changes in retinal vessel density in patients that have been affected by covid-19. the optical coherence tomography angiography represents a noninvasive diagnostic technique that allows a detailed analysis of retinal vascular features.

Eligibility criteria:
inclusion criteria: * age older than 18 years * diagnosis of previous covid-19 * absence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. * absence of significant lens opacities, low-quality oct and oct-a images. exclusion criteria: * age younger than 18 years * absence of previous diagnosis of covid-19 * presence of previous ocular surgery, congenital eye disease, high myopia (\>6 dioptres), actual or previous diagnosis of glaucoma, optic disc anomaly, macular or vitreoretinal diseases. * presence of significant lens opacities, low-quality oct and oct-a images.
national bank alzheimer

Conditions: Alzheimer Disease

Summary: the alzheimer's disease (my) is a major problem of public health. the french national database alzheimer ( bna) registers(records) all the medical acts made by units of memory(report) and of independent specialists in france. in 2008, the national plan alzheimer 2008 - 2012 had for objective to strengthen the search(research) on the alzheimer's disease (my) and for related disorders(confusions), to promote an early diagnosis and to improve at the same time the management of the patients and to support careers(quarries). a specific part(party) of this plan gave rise to the creation of the french national database alzheimer ( bna) to supply epidemiological data as well as indicators of activity. since 2009 the information collected(taken in) in the bna consists of a set(group) limited by data (cima of information minimum corpus alzheimer) concerning the demographic, clinical and diagnostic data defined by national consensus. the number of variables is limited to facilitate and to improve the participation in this national database. the participants are the centers report (cm)((lecture)) and center memory(report) of resources and search(research) (cmrr) and independent specialists. in 2015 more than 500 centers send cima to the bna. the plan disease neurodegenerative 2014 - 2019 wishes to pursue and to amplify the bna.


Eligibility criteria:
inclusion criteria: * patients consulting in french memory centres exclusion criteria: -
a comparative evaluation of the performance and fit of pediatric face masks

Conditions: Healthy

Summary: compare the fit of two pediatric face masks in children.

this is a prospective, randomized, open-label comparative observational study to be conducted in up to two (2) facilities with the healthy and non-healthy subjects (4-12 years of age). the usage of face masks is common practice within hospitals, and masks may be evaluated outside of clinical facilities as well.

Eligibility criteria:
inclusion criteria: * 4 to 12 years of age * conscious exclusion criteria: * able to wear a mask * no previous allergic reactions to face masks

Keywords: pediatric face masks children
detection of schistosomiasis caa in travellers after high-risk water contact

Conditions: Schistosomiasis

Summary: schistosomiasis is increasingly encountered among travellers returning from the tropics and is known for its focal endemicity, associated with the presence of the snail intermediate host in fresh water. because schistosomiasis in travellers is often atypical or asymptomatic due to the low intensity of infection, many infections likely go undiagnosed and will develop into chronic schistosomiasis. conventional treatment of schistosomiasis in travellers with praziquantel 40mg/kg daily dose is known for its modest success rate. diagnosis of schistosomiasis relies on egg detection, which has a poor sensitivity in low burden infections, or serology, which is inadequate to monitor cure. the department of parasitology of the leiden university medical center has developed a novel diagnostic test based on the up-converting phosphor technology (ucp) to detect circulating anodic antigen (caa). this test can be performed on serum and urine to detect low intensity schistosomiasis infections and confirm cure after praziquantel treatment. this study will assess the performance of ucp-caa in travellers with high-risk water contact.


Eligibility criteria:
inclusion criteria: 1. any self-reported high risk water contact, including wading, showering, surfing, walking along wet shore bare-footed or washing with water from a high-risk source, within 12 weeks prior to reporting to the outpatient department 2. agreement to perform routine diagnostic procedures to diagnose schistosomiasis infection 3. willing to provide a maximum of three additional blood samples in addition to routine diagnostic procedures 4. able to provide informed consent exclusion criteria: 1. previous treatment for schistosomiasis 2. known positive schistosomiasis serology 3. the use of immunosuppressive or immunomodulatory drugs at presentation that compromise the interpretation of schistosomiasis serology

Keywords: circulating anodic antigen
patient registry of intrathecal pain management in europe for prialt (ziconotide intrathecal infusion) and alternative drugs for the management of severe, chronic pain.

Conditions: Pain Management; Severe Chronic Pain

Summary: this is an open-label, long-term, multi-center multi-national post-marketing observational registry. the objective of this study is to monitor the long-term efficacy, safety, tolerability and quality of life outcomes associated with ziconotide (prialt) and other analgesics utilized in the intrathecal (it) management of severe chronic pain.

this is an observational non-interventional registry. all patients will sign and date an informed consent form (icf) before enrollment (baseline visit). normal clinical practice will be followed. patients will continue to follow their usual schedule of clinic visits as determined by their physician, during which information and patient-completed questionnaires will be collected (at scheduled intervals timed to coincide with pump refill).

Eligibility criteria:
inclusion criteria patients will be eligible to enroll onto the registry if they have given informed consent and meet the following criteria: * patient's physician has deemed that the initiation/switch of intrathecal analgesia appropriate, or patient is presently utilizing ziconotide (prialt) * patient has a diagnosis of severe, chronic pain for which intrathecal infusion is indicated * patient is at least 18 years of age at time of study entry all patients starting ziconotide (prialt) should comply with the indications and warnings in the current approved version of the summary of product characteristics (smpc). exclusion criteria patients who meet any of the following criteria will not be eligible to enroll in the registry: * patient is a pregnant or lactating female * patient is receiving intrathecal chemotherapy

Keywords: pain management europe intrathecal
efficacy of focused shock waves combined with adjuvant therapy with tendon supplement

Conditions: Fasciitis, Plantar

Summary: physical treatment with focused shock waves is effective in the treatment of tendonitis. food supplements could facilitate the healing of tendinopathies when combined with shock wave therapy.

a single-blind, randomized prospective study (level of evidence ib) was designed. patients with plantar fasciitis were recruited and randomized to group a and group b. group a was treated with focused shock waves alone and group b with a combination of focused shock waves and tendon supplement. pain remission (primary endpoint) and functional recovery (secondary endpoint) are monitored in both groups at three time points (months 0, 3, and 6).

Eligibility criteria:
inclusion criteria: * plantar heel pain diagnosed clinically and instrumentally (ultrasound) as plantar fasciitis, that has not responded to conservative treatment for at least six months; exclusion criteria: * history of previous fractures or ankle and heel surgery; * recurrence of previous local painful episodes; * lesion of the plantar fascia on us examination; * presence of pathologies that affect the function of the foot (lumbar radiculopathy, achilles tendinitis, morton's neuroma, etc.); * chronic inflammatory conditions such as psoriasis, psoriatic arthritis, spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis, chronic inflammatory bowel disease.

Keywords: focused shock waves tendinitis natriuretics
comparative study of ertapenem versus another antibiotic in the treatment of diabetic foot infections in adults (0826-034)

Conditions: Foot Infections in Diabetic Patients

Summary: this study will compare the efficacy, safety and tolerability of intravenous ertapenem versus another intravenous antibiotic in the treatment of moderate to severe diabetic foot infections.


Eligibility criteria:
inclusion criteria: * type 1 or 2 diabetes mellitus treated with diet or medication * clinically or microbiologically documented foot infection below the knee * osteomyelitic bone must be removed within 48 hours of study entry exclusion criteria: * uncomplicated skin infections * infected burn wounds * necrotizing fascitis * wounds with gangrene that cannot be removed with debridement * infections of prosthetic materials * foreign materials that can not be removed by surgical debridement * patients with another antibiotic 3 days prior to enrollment without evidence of treatment failure and presence of a positive culture * insufficient blood flow to the limb requiring a revascularization procedure
investigation of the changes of brain structure and function in premature ejaculation patients and the effects of dapoxetine on central neural activity in premature ejaculation patients

Conditions: Premature Ejaculation

Summary: lifelong premature ejaculation (lpe) is a common male sexual dysfunction with a high prevalence in global. up to now, the etiology of lpe remains unclear. in recent years, dapoxetine, a highly potent serotonin-transporter inhibitor, has been used for treating premature ejaculation. however, the underlying mechanism of dapoxetine was unknown. recently, with widespread use of neuroimaging techniques, like positron emission tomography and magnetic resonance imaging (mri) in basic science, researchers can acquire human data on cerebral base of human sexual behavior, not only in normal subjects but also in patients with sexual dysfunction. therefore, in order to further understand the biological mechanism of lpe and the brain targets of dapoxetine, the present study would investigate the brain changes of lpe and the effect of dapoxetine on brain activation by using mri technology.


Eligibility criteria:
inclusion criteria: * right-handed male chinese volunteers * intravaginal ejaculatory latency time within 1 min * premature ejaculation diagnostic tool score \>11 for patients, but \<5 for each control. * patients who never received dapoxetine hydrochloride or other ssri drugs exclusion criteria: * smokers * had medical，neurological or psychiatric disorders * had alcohol, nicotine, or drug abuse * received any treatment at least 2 weeks before the experiment